Participate in Neuromuscular Clinical Trials Today

Active and recruiting trials

  • The SYNAPSE-SMA Study is a Phase 2 study using NMD670 for those with Spinal Muscular Atrophy. Approximately 54 participants are expected to take part in North America and Europe.

    For more information, please visit clinicaltrials.gov.

    If you are interested in participating, please contact Vincent VEtten@gengepartners.com

  • The Momentum Study is a Phase 2 study using DNTH103 for those with Multifocal Motor Neuropathy. Approximately 36 participants are expected to take part in North America and Europe.

    For more information, please visit clinicaltrials.gov.

    If you are interested in participating, please contact Vincent VEtten@gengepartners.com

Active but not recruiting trials

  • This study is closed for recruitment

    The IBM-201 Study is a Phase 2/3 study using Ulviprubart for those with Inclusion Body Myositis. Approximately 231 participants are expected to take part in North America and Europe.

    For more information, please visit clinicaltrials.gov.

  • This study is closed for recruitment

    The IBM-202 is an extension study using Ulviprubart for those with Inclusion Body Myositis. Approximately 270 participants are expected to take part in North America and Europe.

    For more information, please visit clinicaltrials.gov.

  • This study is closed for recruitment

    The ADAPT-SERON Study is a Phase 2/3 study using Efgartigimod for those with Myasthenia Gravis. Approximately 119 participants are expected to take part in North America and Europe.

    For more information, please visit clinicaltrials.gov.

Upcoming trials

  • The Emvigorate Study is a Phase 3 study using Empasiprubart for those with Chronic Demyelinating Polyradiculoneuropathy. Approximately 218 participants are expected to take part in North America and Europe.

    For more information, please visit clinicaltrials.gov.

    If you are interested in participating, please contact Vincent VEtten@gengepartners.com

If you would like to hear about more about our current or upcoming neurological clinical trials in Montreal please contact us at: info@gengepartners.com

“If we’re not in the beginning for rare disease, we may simply be too late for our patients to get the benefit of these new therapies.”

-Angela Genge

  • Our mission

    To improve patient health and well-being by conducting cutting-edge clinical research. We strive to foster a culture of innovation, collaboration, and excellence in all aspects of our research, and to contribute to the global effort to improve healthcare for all.

  • Our vision

    To be a leading force in advancing medical knowledge and improving patient care through innovative and ethical clinical research

  • Our future

    Genge Partners will continue to be at the forefront of clinical research, utilizing the latest technologies and methodologies to bring new treatments and therapies to patients in need. Our commitment to patient safety, scientific rigor, and ethical conduct will remain steadfast, as we work to improve healthcare for all and make a lasting impact on the field of medicine.

Our facility:

Genge Partners @ Glen
5100 Boul. de Maisonneuve Ouest, 6th floor
Montreal, QC H4A 3TA

 

© 2022 Genge Partners Inc. All rights reserved | Confidentiality policy